title: Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.|Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Ferrero
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Pastore
authors.affiliation: Department of Oncology and Hematology, Vivantes Klinikum, Berlin, Germany.
authors.forename: C W
authors.initials: CW
authors.lastname: Scholz
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Forstpointner
authors.affiliation: Charité University Medicine, Department of Hematology and Oncology, Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Pezzutto
authors.affiliation: Medical Clinic II, University Hospital, Frankfurt, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
authors.affiliation: Department of Hematology and Oncology, Georg-August Universiität, Göttingen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Trümper
authors.affiliation: Hematology/Oncology, University Medical Center, Freiburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Finke
authors.affiliation: III Medical Department, Technische Universität München, Munich, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Keller
authors.affiliation: Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Ghione
authors.affiliation: Biostatistician, Division of Nuclear Medicine, Città della Salute e della Scienza, University of Torino, Torino, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Passera
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Weigert
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Unterhalt
authors.affiliation: Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Dreyling
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D016499:Radioimmunotherapy; D015996:Survival Rate; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan